Sage Therapeutics granted Shionogi exclusive rights to develop and commercialize major depressive disorder drug candidate SAGE-217 in Japan, South Korea and Taiwan. Sage will get an upfront payment of $90 million and up to $485 million for milestones plus royalty fees.
Sage grants Shionogi exclusive rights to MDD drug in 3 countries
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.